Novartis Pharm Drug Patent Portfolio

Novartis Pharm owns 2 orange book drugs protected by 15 US patents Given below is the list of Novartis Pharm's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10596178 Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide 22 Jul, 2035
Active
US7767675 Imidazotriazines and imidazopyrimidines as kinase inhibitors 19 Nov, 2032
Active
US8420645 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same 05 Jun, 2031
Active
US8901123 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same 20 May, 2029
Active
US8461330 Imidazotriazines and imidazopyrimidines as kinase inhibitors 19 Nov, 2027
Active
US8617598 Pharmaceutical compositions comprising colloidal silicon dioxide 27 Mar, 2023 Expired
US8617598 Pharmaceutical compositions comprising colloidal silicon dioxide 27 Sep, 2022 Expired
US8778962 Treatment of solid tumors with rapamycin derivatives 18 Aug, 2022 Expired
US8778962 Treatment of solid tumors with rapamycin derivatives 18 Feb, 2022 Expired
US7297703 Macrolides 06 Jun, 2020 Expired
US5665772 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Mar, 2020 Expired
US7297703 Macrolides 06 Dec, 2019 Expired
US5665772 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Sep, 2019 Expired
US6004973 Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jan, 2017 Expired
US6004973 Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jul, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Novartis Pharm.

Activity Date Patent Number
Patent litigations
Notice of Final Determination -Election Required 18 Apr, 2024 US7767675
Notice of Final Determination -Election Required 18 Apr, 2024 US8420645
Resp. to req. for info. sent under 37 CFR 1.750 08 Dec, 2023 US8420645
Resp. to req. for info. sent under 37 CFR 1.750 08 Dec, 2023 US7767675
Change in Power of Attorney (May Include Associate POA) 20 Nov, 2023 US8901123
Email Notification 20 Nov, 2023 US8461330
Change in Power of Attorney (May Include Associate POA) 20 Nov, 2023 US8461330
Email Notification 20 Nov, 2023 US8901123
Email Notification 19 Sep, 2023 US7767675
Change in Power of Attorney (May Include Associate POA) 19 Sep, 2023 US7767675
Change in Power of Attorney (May Include Associate POA) 19 Sep, 2023 US8420645
Email Notification 19 Sep, 2023 US8420645
Payment of Maintenance Fee, 4th Year, Large Entity 06 Sep, 2023 US10596178
Requirement for information sent under 37 CFR 1.750 29 Aug, 2023 US8420645
Requirement for information sent under 37 CFR 1.750 29 Aug, 2023 US7767675


Novartis Pharm's Drug Patent Litigations

Novartis Pharm's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2015, against patent number US7297703. The petitioner Par Pharmaceutical, Inc., challenged the validity of this patent, with Novartis AG as the respondent. Click below to track the latest information on how companies are challenging Novartis Pharm's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US5665772 October, 2015 FWD Entered
(11 Jan, 2018)
Novartis AG Par Pharmaceutical, Inc.
US5665772 May, 2016 FWD Entered
(27 Oct, 2016)
Novartis AG BRECKENRIDGE PHARMACEUTICAL, INC.
US5665772 May, 2016 Terminated-Denied
(27 Oct, 2016)
Novartis AG Par Pharmaceutical, Inc.
US5665772 May, 2016 FWD Entered
(27 Oct, 2016)
Novartis AG Roxane Laboratories, Inc.
US5665772 May, 2016 Terminated-Denied
(27 Oct, 2016)
Novartis AG Breckenridge Pharmaceutical, Inc.
US7297703 October, 2015 Terminated-Denied
(01 Apr, 2016)
Novartis AG Par Pharmaceutical, Inc.


Novartis Pharm Drug Patents' Oppositions Filed in EPO

Novartis Pharm drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 18, 2016, by Teva Pharmaceutical Industries Ltd. This opposition was filed on patent number EP10174983A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP18155722A Jan, 2023 Generics [UK] Limited Granted and Under Opposition
EP18155722A Jan, 2023 Ethypharm Granted and Under Opposition
EP18155722A Jan, 2023 STADA Arzneimittel AG Granted and Under Opposition
EP15744702A Sep, 2021 D Young & Co LLP Granted and Under Opposition
EP18155724A Jun, 2020 ARROW GENERIQUES Granted and Under Opposition
EP18155724A May, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP18155724A May, 2020 Zentiva k.s. Granted and Under Opposition
EP18155724A May, 2020 Generics [UK] Ltd Granted and Under Opposition
EP18155724A Apr, 2020 PUREN Pharma GmbH & Co. KG Granted and Under Opposition
EP18155644A Feb, 2020 ARROW GENERIQUES Granted and Under Opposition
EP18155644A Feb, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP18155644A Feb, 2020 Generics [UK] Limited Granted and Under Opposition
EP18155724A Feb, 2020 Ethypharm Granted and Under Opposition
EP18155644A Jan, 2020 Dr. Reddy's Laboratories Limited Granted and Under Opposition
EP18155724A Sep, 2019 BIOGARAN Granted and Under Opposition
EP18155644A Sep, 2019 Zentiva Pharma GmbH Granted and Under Opposition
EP16186041A Sep, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP16186041A Sep, 2019 Generics [UK] Ltd Granted and Under Opposition
EP16186041A Sep, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP16186041A Sep, 2019 Zentiva k.s. Granted and Under Opposition
EP16186041A Aug, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP16186041A Aug, 2019 Synthon B.V. Granted and Under Opposition
EP18155724A Aug, 2019 Dr. Reddy's Laboratories / Betapharm Arzneimittel GmbH Granted and Under Opposition
EP18155724A Aug, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP18155724A Aug, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP18155644A Jul, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP10174983A Jul, 2019 Zentiva France Revoked
EP18155644A Jul, 2019 Ethypharm Granted and Under Opposition
EP18155644A Jul, 2019 BIOGARAN Granted and Under Opposition
EP16186041A Jun, 2019 Ethypharm Granted and Under Opposition
EP18155644A May, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP09751439A Apr, 2018 Generics (U.K.) Limited Granted and Under Opposition
EP14164259A Mar, 2018 Generics (UK) Ltd Revoked
EP14164565A Dec, 2017 Ethypharm Revoked
EP14164565A Dec, 2017 Generics (U.K.) Limited Revoked
EP10174985A Apr, 2017 STADA Arzneimittel AG Revoked
EP10174985A Apr, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP10174985A Apr, 2017 Generics [UK] Ltd Revoked
EP10174985A Apr, 2017 Intas Pharmaceuticals Ltd. Revoked
EP10174985A Apr, 2017 Wittkopp, Alexander Revoked
EP10174985A Apr, 2017 Fresenius Kabi Deutschland GmbH Revoked
EP10174985A Apr, 2017 KRKA, d.d., Novo mesto Revoked
EP10174985A Apr, 2017 Synthon Biopharmaceuticals B.V. Revoked
EP10174983A Feb, 2016 Synthon B.V. Revoked
EP10174983A Feb, 2016 Wittkopp, Alexander Revoked
EP10174983A Feb, 2016 Actavis PTC ehf Revoked
EP10174983A Feb, 2016 Intas Pharmaceuticals Ltd. Revoked
EP10174983A Feb, 2016 STADA Arzneimittel AG Revoked
EP10174983A Feb, 2016 Ethypharm Revoked
EP10174983A Feb, 2016 Generics [UK] Limited Revoked
EP10174983A Feb, 2016 Teva Pharmaceutical Industries Ltd Revoked


Novartis Pharm's Family Patents

Novartis Pharm drugs have patent protection in a total of 51 countries. It's US patent count contributes only to 10.5% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Novartis Pharm Drug List

Given below is the complete list of Novartis Pharm's drugs and the patents protecting them.


1. Afinitor Disperz

Afinitor Disperz is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8617598
(Pediatric)
Pharmaceutical compositions comprising colloidal silicon dioxide 27 Mar, 2023
(1 year, 6 months ago)
Expired
US8617598 Pharmaceutical compositions comprising colloidal silicon dioxide 27 Sep, 2022
(2 years ago)
Expired
US8778962
(Pediatric)
Treatment of solid tumors with rapamycin derivatives 18 Aug, 2022
(2 years ago)
Expired
US8778962 Treatment of solid tumors with rapamycin derivatives 18 Feb, 2022
(2 years ago)
Expired
US7297703
(Pediatric)
Macrolides 06 Jun, 2020
(4 years ago)
Expired
US5665772
(Pediatric)
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Mar, 2020
(4 years ago)
Expired
US7297703 Macrolides 06 Dec, 2019
(4 years ago)
Expired
US5665772 O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants 09 Sep, 2019
(5 years ago)
Expired
US6004973
(Pediatric)
Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jan, 2017
(7 years ago)
Expired
US6004973 Pharmaceutical compositions comprising rafamycin coprecipitates 12 Jul, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Afinitor Disperz's drug page


2. Tabrecta

Tabrecta is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10596178 Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide 22 Jul, 2035
(10 years from now)
Active
US7767675 Imidazotriazines and imidazopyrimidines as kinase inhibitors 19 Nov, 2032
(8 years from now)
Active
US8420645 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same 05 Jun, 2031
(6 years from now)
Active
US8901123 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same 20 May, 2029
(4 years from now)
Active
US8461330 Imidazotriazines and imidazopyrimidines as kinase inhibitors 19 Nov, 2027
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tabrecta's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List